HIV与丙型肝炎共感染者直接抗病毒治疗前后肝脂肪变性的变化
在加拿大共感染队列中,431名HIV/HCV共感染者接受直接抗病毒药物(DAA)成功治疗,用受控衰减参数(CAP)和肝脂肪变性指数(HSI)评估肝脂肪变性(HS)。CAP在治疗前后均持续上升,而HSI仅在治疗期间明显下降,提示HSI可能反映肝脏炎症消退而非HS改善。
要点
- CAP在DAA治疗前年均斜率3.3 dB/m,治疗后3.9 dB/m,均持续上升。
- HSI治疗前年均斜率0.2,治疗后0.2,变化很小;治疗期间下降-4.5。
- HSI下降可能反映肝脏炎症消退,而非肝脂肪变性改善。
核心结论
- 以CAP评估时,肝脂肪变性不受DAA治疗影响并随时间持续增加;HSI不反映肝脂肪变性变化,治疗期间下降可能与肝脏炎症消退有关。
- 已治愈HCV的共感染者持续存在的肝脂肪变性可能构成肝病风险。
研究设计与样本
- 加拿大共感染队列中HIV与HCV共感染参与者,采用受控衰减参数(CAP)和肝脂肪变性指数(HSI)评估肝脂肪变性。
- 使用广义加性混合模型估计DAA成功治疗前、中、后肝脂肪变性变化,并校正治疗前测量的年龄、性别、HCV感染时长、体重指数、糖尿病、既往二脱氧核苷暴露和有害饮酒。
- 共纳入431名治疗前至少有1次CAP或HSI测量的参与者。
主要发现
- CAP随时间稳定上升:治疗前校正年斜率3.3 dB/m(95%可信区间[CrI],1.6-4.9),治疗后3.9 dB/m(95% CrI,1.9-5.9),与治疗前CAP水平无关。
- HSI随时间变化很小:治疗前年斜率0.2(95% CrI,-0.1至0.5),治疗后0.2(95% CrI,-0.1至0.5),但治疗期间显示明显下降-4.5(95% CrI,-5.9至-3.1)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections increase the risk of hepatic steatosis (HS), which in turn contribute to the severity and progression of liver disease. Direct-acting antivirals (DAAs) can cure HCV but whether they reduce HS is unclear. METHODS: HS was assessed using the controlled attenuation parameter (CAP) and the Hepatic Steatosis Index (HSI) in participants coinfected with HIV and HCV from the Canadian Coinfection Cohort. Changes in HS, before, during, and after successful DAA treatment were estimated using generalized additive mixed models, adjusted for covariates measured prior to treatment (age, sex, duration of HCV infection, body mass index, diabetes, prior exposure to dideoxynucleosides, and hazardous drinking). RESULTS: In total, 431 participants with at least 1 measure of CAP or HSI before treatment were included. CAP steadily increased over time: adjusted annual slope 3.3 dB/m (95% credible interval [CrI], 1.6-4.9) before, and 3.9 dB/m (95% CrI, 1.9-5.9) after DAA treatment, irrespective of pretreatment CAP. In contrast, HSI changed little over time: annual slope 0.2 (95% CrI, -0.1 to 0.5) before and 0.2 (95% CrI, -0.1 to 0.5) after, but demonstrated a marked reduction during treatment -4.5 (95% CrI, -5.9 to -3.1). CONCLUSIONS: When assessed by CAP, HS was unaffected by DAA treatment and steadily increased over time. In contrast, HSI did not appear to reflect changes in HS, with the decrease during treatment likely related to resolution of hepatic inflammation. Ongoing HS may pose a risk for liver disease in coinfected people cured of HCV.
引用
- Truscello E, Wang S, Young J, et al. Changes in Hepatic Steatosis Before and After Direct-Acting Antiviral Treatment in People With HIV and Hepatitis C Coinfection. J Infect Dis. 2025. PMID: 39417816. doi:10.1093/infdis/jiae487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。